Journal of Pathology and Translational Medicine

Original Article

High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy: Bobae Shim, Min‐Sun Jin, Ji Hye Moon, In Ae Park, Han Suk Ryu; J Pathol Transl Med. 2018;52(6):369-377. Published online October 1, 2018; DOI: https://doi.org/10.4132/jptm.2018.09.19

11,714 View
158 Download
7 Web of Science
9 Crossref

Background
Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies have reported that increased CXCR4 expression is associated with worse prognosis in triple-negative breast cancer (TNBC), but its prognostic significance has not been studied in TNBC patients treated with adjuvant chemotherapy.
Methods
Two hundred eighty-three TNBC patients who received adjuvant chemotherapy were retrospectively analyzed. Tissue microarray was constructed from formalinfixed, paraffin-embedded tumor tissue and immunohistochemistry for CXCR4 and CXCL12 was performed. Expression of each marker was compared with clinicopathologic characteristics and outcome.
Results
High cytoplasmic CXCR4 expression was associated with younger age (p = .008), higher histologic grade (p = .007) and lower pathologic stage (p = .045), while high CXCL12 expression was related to larger tumor size (p = .045), positive lymph node metastasis (p = .005), and higher pathologic stage (p = .017). The patients with high cytoplasmic CXCR4 experienced lower distant recurrence (p = .006) and better recurrence-free survival (RFS) (log-rank p = .020) after adjuvant chemotherapy. Cytoplasmic CXCR4 expression remained an independent factor of distant recurrence (p = .019) and RFS (p = .038) after multivariate analysis.
Conclusions
High cytoplasmic CXCR4 expression was associated with lower distant recurrence and better RFS in TNBC patients treated with adjuvant chemotherapy. This is the first study to correlate high CXCR4 expression to better TNBC prognosis, and the underlying mechanism needs to be elucidated in further studies.

Citations

Citations to this article as recorded by

Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes
Konstantinos Ntostoglou, Sofia D. P. Theodorou, Tanja Proctor, Ilias P. Nikas, Sinclair Awounvo, Athanasia Sepsa, Vassilis Georgoulias, Han Suk Ryu, Ioannis S. Pateras, Christos Kittas
Cancer Immunology, Immunotherapy.2024;[Epub] CrossRef
Unravelling the CXCL12/CXCR4 Axis in breast cancer: Insights into metastasis, microenvironment interactions, and therapeutic opportunities
Priyanka Garg, Venkateswara Rao Jallepalli, Sonali Verma
Human Gene.2024; 40: 201272. CrossRef
Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study
Shuai Lin, Yi Zheng, Meng Wang, Linghui Zhou, Yuyao Zhu, Yujiao Deng, Ying Wu, Dai Zhang, Na Li, Huafeng Kang, Zhijun Dai
Molecular Biology Reports.2022; 49(3): 2255. CrossRef
The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis
Liping Qiu, Yuanyuan Xu, Hui Xu, Biyun Yu
BMC Cancer.2022;[Epub] CrossRef
Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm
Mushtaq Ahmad Nengroo, Muqtada Ali Khan, Ayushi Verma, Dipak Datta
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(5): 188790. CrossRef
Targeted dendrimers for antagonizing the migration and viability of NALM-6 lymphoblastic leukemia cells
Chuda Chittasupho, Chaiyawat Aonsri, Witcha Imaram
Bioorganic Chemistry.2021; 107: 104601. CrossRef
CXCR4 and RANK Combination as a Predictor of Breast Cancer Bone Metastasis in Indonesia
Yulian Erwin D
Journal of Surgery and Surgical Research.2021; : 020. CrossRef
CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
Keywan Mortezaee
Life Sciences.2020; 249: 117534. CrossRef
Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma
Irina Chifu, Britta Heinze, Carmina T. Fuss, Katharina Lang, Matthias Kroiss, Stefan Kircher, Cristina L. Ronchi, Barbara Altieri, Andreas Schirbel, Martin Fassnacht, Stefanie Hahner
Frontiers in Endocrinology.2020;[Epub] CrossRef

Review

Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer: Sung Gwe Ahn, Joon Jeong, SoonWon Hong, Woo Hee Jung; J Pathol Transl Med. 2015;49(5):355-363. Published online August 17, 2015; DOI: https://doi.org/10.4132/jptm.2015.07.29

12,810 View
227 Download
38 Web of Science
32 Crossref

Abstract PDF

With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2–positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.

Citations

Citations to this article as recorded by

Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer
Hongyu Gao, Dengjie Ouyang, Xinyu Guan, Jiachi Xu, Qitong Chen, Liyun Zeng, Jian Pang, Qiongyan Zou, Ke Qian, Wenjun Yi
BMC Cancer.2024;[Epub] CrossRef
Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics
Chenglu Jiang, Shengke Zhang, Lai Jiang, Zipei Chen, Haiqing Chen, Jinbang Huang, Jingyi Tang, Xiufang Luo, Guanhu Yang, Jie Liu, Hao Chi
Environmental Toxicology.2024;[Epub] CrossRef
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
Uiju Cho, Soyoung Im, Hyung Soon Park
Journal of Pathology and Translational Medicine.2024; 58(2): 49. CrossRef
Predictive and Prognostic Role of Tumor‐Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy
Gaurav Agarwal, K. M. M. Vishvak Chanthar, Shweta Katiyar, Niraj Kumari, Narendra Krishnani, M. Sabaretnam, Gyan Chand, Anjali Mishra, Punita Lal
World Journal of Surgery.2023; 47(5): 1238. CrossRef
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
Ruonan Li, Lili Cao
Frontiers in Immunology.2023;[Epub] CrossRef
Using Self-Assembling ADDomer Platform to Display B and T Epitopes of Type O Foot-and-Mouth Disease Virus
Chaowei Luo, Quanhui Yan, Juncong Huang, Jiameng Liu, Yuwan Li, Keke Wu, Bingke Li, Mingqiu Zhao, Shuangqi Fan, Hongxing Ding, Jinding Chen
Viruses.2022; 14(8): 1810. CrossRef
Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
Guilan Shi, Megan Scott, Cathryn G. Mangiamele, Richard Heller
Pharmaceutics.2022; 14(11): 2429. CrossRef
Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy
Bacinschi Xenia Elena, Laurentia Nicoleta Gales, Anca Florina Zgura, Laura Iliescu, Rodica Maricela Anghel, Bogdan Haineala, Xiaosheng Wang
Journal of Oncology.2021; 2021: 1. CrossRef
Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma
Kyung Un Choi, Ahrong Kim, Jee Yeon Kim, Ki Hyung Kim, Chungsu Hwang, So Jung Lee, Won Young Park, Sejin Jung, Hye Jeong Choi, Kyungbin Kim
Journal of Ovarian Research.2020;[Epub] CrossRef
Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review

Weilin Xu, Xiu Chen, Fei Deng, Jian Zhang, Wei Zhang, Jinhai Tang
OncoTargets and Therapy.2020; Volume 13: 5887. CrossRef
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
Sandra V. Fernandez, Alexander W. MacFarlane, Mowafaq Jillab, Maria F. Arisi, Jennifer Yearley, Lakshmanan Annamalai, Yulan Gong, Kathy Q. Cai, R. Katherine Alpaugh, Massimo Cristofanilli, Kerry S. Campbell
Breast Cancer Research.2020;[Epub] CrossRef
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
C. Van Berckelaer, C. Rypens, P. van Dam, L. Pouillon, M. Parizel, K. A. Schats, M. Kockx, W. A. A. Tjalma, P. Vermeulen, S. van Laere, F. Bertucci, C. Colpaert, L. Dirix
Breast Cancer Research.2019;[Epub] CrossRef
The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status
Anna Glajcar, Joanna Szpor, Diana Hodorowicz-Zaniewska, Katarzyna Ewa Tyrak, Krzysztof Okoń
Virchows Archiv.2019; 475(1): 13. CrossRef
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
Ana S. Leal, Kayla Zydeck, Sarah Carapellucci, Lyndsey A. Reich, Di Zhang, Jessica A. Moerland, Michael B. Sporn, Karen T. Liby
npj Breast Cancer.2019;[Epub] CrossRef
Stromal tumor‑infiltrating lymphocytes evaluated on H&E‑stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma
Chungsu Hwang, So Lee, Jung Lee, Ki Kim, Dong Suh, Byung‑Su Kwon, Kyung Choi
Oncology Letters.2019;[Epub] CrossRef
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, Mitsugu Yamamoto, Masako Sato, Ken-ichi Watanabe, Katsushige Yamashiro, Masato Takahashi
Breast Cancer.2018; 25(1): 34. CrossRef
Triple negative breast cancer – prognostic role of immune-related factors: a systematic review
Elisabeth Specht Stovgaard, Dorte Nielsen, Estrid Hogdall, Eva Balslev
Acta Oncologica.2018; 57(1): 74. CrossRef
Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells
Julian Gomez-Cambronero
Cancer and Metastasis Reviews.2018; 37(2-3): 491. CrossRef
Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers
So Jeong Lee, Cheong-Soo Hwang, Young-Keum Kim, Hyun Jung Lee, Sang-Jeong Ahn, Nari Shin, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Do Youn Park, Chang Hun Lee, Gi Young Huh, Mi Young Sol, Hee Jin Lee, Gyungyub Gong, Jee Yeon Kim, Ahrong Kim
Cancer Research and Treatment.2017; 49(2): 313. CrossRef
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes
Joo Young Kim, Sun-Hee Heo, Seul Ki Choi, In Hye Song, In Ah Park, Young-Ae Kim, Hye Seon Park, Suk Young Park, Won Seon Bang, Gyungyub Gong, Hee Jin Lee
Virchows Archiv.2017; 470(4): 381. CrossRef
Whole Slide Imaging for Analytical Anatomic Pathology and Telepathology: Practical Applications Today, Promises, and Perils
Alton Brad Farris, Cynthia Cohen, Thomas E. Rogers, Geoffrey H. Smith
Archives of Pathology & Laboratory Medicine.2017; 141(4): 542. CrossRef
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility
Andrea Ravelli, Giandomenico Roviello, Daniele Cretella, Andrea Cavazzoni, Alessandra Biondi, Maria Rosa Cappelletti, Laura Zanotti, Giuseppina Ferrero, Marco Ungari, Fabrizio Zanconati, Alberto Bottini, Roberta Alfieri, Pier Giorgio Petronini, Daniele Ge
Tumor Biology.2017; 39(4): 101042831769502. CrossRef
Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
In Hye Song, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, In Ah Park, Young-Ae Kim, Suk Young Park, Jin Roh, Gyungyub Gong, Hee Jin Lee
Cancer Research and Treatment.2017; 49(2): 399. CrossRef
Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?
Weiwei Zhao, Peng Wang, Huixun Jia, Menglei Chen, Xiaoli Gu, Minghui Liu, Zhe Zhang, Wenwu Cheng, Zhenyu Wu
BMC Cancer.2017;[Epub] CrossRef
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
Ahrong Kim, So Jeong Lee, Young Keum Kim, Won Young Park, Do Youn Park, Jee Yeon Kim, Chang Hun Lee, Gyungyub Gong, Gi Yeong Huh, Kyung Un Choi
Scientific Reports.2017;[Epub] CrossRef
Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer
Kyueng-Whan Min, Dong-Hoon Kim, Sung-Im Do, Seoung Wan Chae, Kyungeun Kim, Jin Hee Sohn, Jung-Soo Pyo, Hyun Joo Lee, Dong Hyun Kim, Sukjoong Oh, Seon Hyeong Choi, Yong Lai Park, Chan Heun Park, Eun-Kyung Kim, Mi Jung Kwon, Jinwon Seo, Kyoung Min Moon
Virchows Archiv.2016; 468(4): 409. CrossRef
Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor‐infiltrating lymphocytes (TILs) in breast cancer
Hee Jin Lee, Ahrong Kim, In Hye Song, In Ah Park, Jong Han Yu, Jin Hee Ahn, Gyungyub Gong
Pathology International.2016; 66(4): 202. CrossRef
Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy
Kyu-pyo Kim, Hun Jung
Translational and Clinical Pharmacology.2016; 24(1): 7. CrossRef
The next level of 3D tumour models: immunocompetence
Agata Nyga, Joana Neves, Katerina Stamati, Marilena Loizidou, Mark Emberton, Umber Cheema
Drug Discovery Today.2016; 21(9): 1421. CrossRef
An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes
Ahrong Kim, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee
American Journal of Clinical Pathology.2016; 146(1): 137. CrossRef
High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer
Kyueng-Whan Min, Dong-Hoon Kim, Sung-Im Do, Jung-Soo Pyo, Seoung Wan Chae, Jin Hee Sohn, Kyungeun Kim, Hyun Joo Lee, Dong Hyun Kim, Sukjoong Oh, Seon Hyeong Choi, Yong Lai Park, Chan Heun Park, Mi Jung Kwon, Kyoung Min Moon
Postgraduate Medical Journal.2016; 92(1094): 707. CrossRef
Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Changro Lee, Seho Park, Joo Heung Kim, Sung Mook Lim, Hyung Seok Park, Seung Il Kim, Byeong-Woo Park
Journal of Breast Cancer.2016; 19(4): 385. CrossRef

First
Prev
Page of 1
Next
Last

Search